Clinical Trial Update: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating combinations of inotuzumab ozogamicin, blinatumomab with or without ponatinib for newly diagnosed, recurrent, or refractory CD2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• Besponsa (inotuzumab ozogamicin)
• Iclusig (ponatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Status: RECRUITING